JP6208866B2 - 硫酸化オリゴ糖を検出する分析法 - Google Patents
硫酸化オリゴ糖を検出する分析法 Download PDFInfo
- Publication number
- JP6208866B2 JP6208866B2 JP2016525337A JP2016525337A JP6208866B2 JP 6208866 B2 JP6208866 B2 JP 6208866B2 JP 2016525337 A JP2016525337 A JP 2016525337A JP 2016525337 A JP2016525337 A JP 2016525337A JP 6208866 B2 JP6208866 B2 JP 6208866B2
- Authority
- JP
- Japan
- Prior art keywords
- mobile phase
- hilic
- sample
- column
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000002482 oligosaccharides Chemical class 0.000 title claims description 39
- 229920001542 oligosaccharide Polymers 0.000 title claims description 38
- 238000004458 analytical method Methods 0.000 title description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 31
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical group [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims description 24
- 238000002013 hydrophilic interaction chromatography Methods 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 17
- 230000005526 G1 to G0 transition Effects 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 13
- 229960001318 fondaparinux Drugs 0.000 claims description 12
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 claims description 12
- 239000000443 aerosol Substances 0.000 claims description 9
- 239000012535 impurity Substances 0.000 claims description 9
- 230000003993 interaction Effects 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 6
- 239000005695 Ammonium acetate Substances 0.000 claims description 6
- 229940043376 ammonium acetate Drugs 0.000 claims description 6
- 235000019257 ammonium acetate Nutrition 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 238000001195 ultra high performance liquid chromatography Methods 0.000 claims description 6
- FDTUVFSBEYKVAP-UHFFFAOYSA-N formic acid;pyridine Chemical compound OC=O.C1=CC=NC=C1 FDTUVFSBEYKVAP-UHFFFAOYSA-N 0.000 claims description 5
- 238000004704 ultra performance liquid chromatography Methods 0.000 claims 4
- 125000003368 amide group Chemical group 0.000 claims 1
- XEKSTYNIJLDDAZ-JASSWCPGSA-D decasodium;(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4-hydroxy-6-[(2r,3s,4r,5r,6s)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxyoxan-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sul Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O[C@@H]1[C@@H](NS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OS([O-])(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS([O-])(=O)=O)O4)NS([O-])(=O)=O)[C@H](O3)C([O-])=O)O)[C@@H](COS([O-])(=O)=O)O2)NS([O-])(=O)=O)[C@H](C([O-])=O)O1 XEKSTYNIJLDDAZ-JASSWCPGSA-D 0.000 description 17
- 229960003661 fondaparinux sodium Drugs 0.000 description 15
- 238000004949 mass spectrometry Methods 0.000 description 13
- 238000001514 detection method Methods 0.000 description 10
- 238000011002 quantification Methods 0.000 description 10
- -1 sulfoamino Chemical group 0.000 description 9
- 230000014759 maintenance of location Effects 0.000 description 8
- 239000003643 water by type Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000000926 separation method Methods 0.000 description 6
- 229920002971 Heparan sulfate Polymers 0.000 description 5
- 238000012369 In process control Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 150000001408 amides Chemical group 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 238000002305 strong-anion-exchange chromatography Methods 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- 229920001499 Heparinoid Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- 239000013016 formulated drug substance Substances 0.000 description 2
- 239000002554 heparinoid Substances 0.000 description 2
- 229940025770 heparinoids Drugs 0.000 description 2
- 239000003055 low molecular weight heparin Substances 0.000 description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 229940104697 arixtra Drugs 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- XFQYJNINHLZMIU-UHFFFAOYSA-N cataline Natural products CN1CC(O)C2=CC(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(OC)=C1 XFQYJNINHLZMIU-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010965 in-process control Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- GAPYKZAARZMMGP-UHFFFAOYSA-N pyridin-1-ium;acetate Chemical compound CC(O)=O.C1=CC=NC=C1 GAPYKZAARZMMGP-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/30—Partition chromatography
- B01D15/305—Hydrophilic interaction chromatography [HILIC]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C08B37/0078—Degradation products
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8836—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving saccharides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2013/050147 WO2015005928A1 (fr) | 2013-07-11 | 2013-07-11 | Procédé analytique pour détecter des oligosaccharides sulfatés |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016524166A JP2016524166A (ja) | 2016-08-12 |
| JP6208866B2 true JP6208866B2 (ja) | 2017-10-04 |
Family
ID=52280428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525337A Expired - Fee Related JP6208866B2 (ja) | 2013-07-11 | 2013-07-11 | 硫酸化オリゴ糖を検出する分析法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3019861A4 (fr) |
| JP (1) | JP6208866B2 (fr) |
| KR (1) | KR20160030963A (fr) |
| CN (1) | CN105431733B (fr) |
| AU (1) | AU2013393832B2 (fr) |
| CA (1) | CA2917460A1 (fr) |
| IL (1) | IL243405A0 (fr) |
| WO (1) | WO2015005928A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201610633QA (en) | 2014-06-26 | 2017-01-27 | Regeneron Pharma | Methods and compositions for targeted genetic modifications and methods of use |
| JP6706497B2 (ja) * | 2015-12-24 | 2020-06-10 | 昭和電工株式会社 | 親水性化合物の分離分析方法 |
| CN105628820A (zh) * | 2016-01-08 | 2016-06-01 | 东营天东制药有限公司 | 一种低分子肝素生产过程中游离硫酸根离子快速检测方法 |
| US11510871B2 (en) | 2016-09-16 | 2022-11-29 | Leukocare Ag | Method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation |
| CN109952372A (zh) | 2016-09-16 | 2019-06-28 | 白血球保健股份有限公司 | 获得有效用于疫苗接种或基因治疗的基于病毒载体的组合物的新方法 |
| CN110709696B (zh) * | 2017-06-22 | 2022-01-04 | 昭和电工株式会社 | 寡核苷酸的混合物的分离分析方法 |
| CN109254101B (zh) * | 2017-07-13 | 2021-07-09 | 中国科学院大连化学物理研究所 | 一种母乳酸性寡糖净化和分析方法 |
| CN109459523B (zh) * | 2017-09-06 | 2022-11-08 | 上海绿谷制药有限公司 | 一种测定酸性糖可溶性盐重均分子量和含量的方法 |
| CN116879411A (zh) * | 2018-07-24 | 2023-10-13 | 深圳市海普瑞药业集团股份有限公司 | 一种达肝素钠亚硝酸降解产物的分析方法及其应用 |
| CN112154325B (zh) * | 2018-07-26 | 2023-02-14 | 深圳市海普瑞药业集团股份有限公司 | 低分子肝素糖链分布的分析方法及其应用 |
| CN111239311A (zh) * | 2018-11-28 | 2020-06-05 | 中国科学院大连化学物理研究所 | 一种婴幼儿排泄物中酸性糖及酸性糖衍生物的分析方法 |
| CN109633003A (zh) * | 2018-12-26 | 2019-04-16 | 成都普思生物科技股份有限公司 | 一种测定远志中远志口山酮ⅲ和3,6，-二芥子酰基蔗糖含量的方法 |
| CN110161147A (zh) * | 2019-06-19 | 2019-08-23 | 北京三元食品股份有限公司 | 乳中游离低聚糖的高通量定量测定方法 |
| JP7487987B1 (ja) | 2023-12-21 | 2024-05-21 | 伊那食品工業株式会社 | アガロオリゴ糖の分析方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162938A1 (en) * | 2005-11-08 | 2009-06-25 | Suomen Punainen Risti,Veripalvelu | Novel Carbohydrate Profile Compositions From Human Cells and Methods for Analysis and Modification Thereof |
| WO2008150488A1 (fr) * | 2007-06-01 | 2008-12-11 | Laboratory Corporation Of America Holdings | Procédés et systèmes de quantification de peptides et d'autres analytes |
| US8696917B2 (en) * | 2009-02-09 | 2014-04-15 | Edwards Lifesciences Corporation | Analyte sensor and fabrication methods |
| EP2306199A1 (fr) * | 2009-09-29 | 2011-04-06 | Academisch Ziekenhuis Leiden Acting Under The Name Leiden University Medical Center | L'amination réductrice et l'analyse des glucides en utilisant le borane de 2-picoline comme agent de réduction |
| CN102101875A (zh) * | 2009-12-16 | 2011-06-22 | 中国科学院大连化学物理研究所 | 一种寡糖纯化分离方法 |
| AU2010332797B2 (en) * | 2009-12-18 | 2015-05-28 | Catalent Pharma Solutions Gmbh | Pharmaceutical oral dosage form containing a synthetic oligosaccharide |
| US20110178104A1 (en) * | 2010-01-07 | 2011-07-21 | Polymedix Inc. | Anti-Heparin Compounds |
| CN102759596B (zh) * | 2012-07-09 | 2014-08-20 | 山东大学 | 一种低分子肝素的离子对反相色谱质谱联用检测方法 |
-
2013
- 2013-07-11 AU AU2013393832A patent/AU2013393832B2/en not_active Expired - Fee Related
- 2013-07-11 JP JP2016525337A patent/JP6208866B2/ja not_active Expired - Fee Related
- 2013-07-11 KR KR1020167003059A patent/KR20160030963A/ko not_active Application Discontinuation
- 2013-07-11 CN CN201380078160.1A patent/CN105431733B/zh not_active Expired - Fee Related
- 2013-07-11 CA CA2917460A patent/CA2917460A1/fr not_active Abandoned
- 2013-07-11 WO PCT/US2013/050147 patent/WO2015005928A1/fr active Application Filing
- 2013-07-11 EP EP13888999.3A patent/EP3019861A4/fr not_active Withdrawn
-
2015
- 2015-12-30 IL IL243405A patent/IL243405A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105431733A (zh) | 2016-03-23 |
| CA2917460A1 (fr) | 2015-01-15 |
| WO2015005928A1 (fr) | 2015-01-15 |
| IL243405A0 (en) | 2016-02-29 |
| JP2016524166A (ja) | 2016-08-12 |
| EP3019861A1 (fr) | 2016-05-18 |
| KR20160030963A (ko) | 2016-03-21 |
| EP3019861A4 (fr) | 2017-02-22 |
| AU2013393832A1 (en) | 2016-02-04 |
| AU2013393832B2 (en) | 2017-11-30 |
| CN105431733B (zh) | 2019-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6208866B2 (ja) | 硫酸化オリゴ糖を検出する分析法 | |
| Ćirić et al. | Evaluation of matrix effect in determination of some bioflavonoids in food samples by LC–MS/MS method | |
| Vlčková et al. | Current state of bioanalytical chromatography in clinical analysis | |
| Chaves et al. | Microextraction in packed sorbent for analysis of antidepressants in human plasma by liquid chromatography and spectrophotometric detection | |
| D’Orazio et al. | Nano-liquid chromatography coupled with mass spectrometry: Separation of sulfonamides employing non-porous core–shell particles | |
| Szultka et al. | A new approach for antibiotic drugs determination in human plasma by liquid chromatography–mass spectrometry | |
| Figueiredo et al. | Quantitation of drugs via molecularly imprinted polymer solid phase extraction and electrospray ionization mass spectrometry: benzodiazepines in human plasma | |
| Roda et al. | Development and validation of a sensitive HPLC–ESI-MS/MS method for the direct determination of glucosamine in human plasma | |
| US20210132086A1 (en) | Mass spectrometric determination of derivatized methylmalonic acid | |
| Jiang et al. | Determination of carboplatin in human plasma using HybridSPE-precipitation along with liquid chromatography–tandem mass spectrometry | |
| CN110441449B (zh) | 盐酸法舒地尔原料或注射剂中有关物质的检测方法 | |
| Domingues et al. | Simultaneous determination of amino acids and neurotransmitters in plasma samples from schizophrenic patients by hydrophilic interaction liquid chromatography with tandem mass spectrometry | |
| Song et al. | A capillary liquid chromatographic/tandem mass spectrometric method for the quantification of γ-aminobutyric acid in human plasma and cerebrospinal fluid | |
| US9441053B2 (en) | Analytical method for detecting sulfated oligosaccharides | |
| Huang et al. | Development of a simple method for quantitation of methanesulfonic acid at low ppm level using hydrophilic interaction chromatography coupled with ESI-MS | |
| Kaufmann et al. | Simplifying nontargeted analysis of PFAS in complex food matrixes | |
| CN103344731A (zh) | 离子色谱质谱联用仪定性定量测定食品中糖醇的方法 | |
| JP2008527390A (ja) | 血漿からオリゴ糖を分析するための方法 | |
| JP2016538574A (ja) | ジアンヒドロガラクチトール中の不純物のｈｐｌｃ分析 | |
| JP2020530904A (ja) | マススペクトロメトリーによるグアニジノ酢酸、クレアチン、及びクレアチニンの検出及び定量 | |
| Ion et al. | Determination of iohexol by capillary blood microsampling and UHPLC-MS/MS | |
| Bertolini et al. | A novel automated hydrophilic interaction liquid chromatography method using diode-array detector/electrospray ionization tandem mass spectrometry for analysis of sodium risedronate and related degradation products in pharmaceuticals | |
| Kim et al. | Determination of dapoxetine in rat plasma by ultra-performance liquid chromatography–tandem mass spectrometry | |
| CN104833761A (zh) | 一种快速分析样品中的糖类化合物的方法 | |
| Song et al. | Simultaneous determination of 14 biogenic amines and metabolites in bullfrog blood using UFLC-MS/MS with SPE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20161125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170303 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170808 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170907 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6208866 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |